The elevation of PD-L1 following CHK1 targeting was additionally validated by subjecting cells to a second CHK1 inhibitor, LY2603618 (also known as Rabusertib, manufactured by Eli Lilly and Company, Indianapolis, IN, United States), in SCLC cell lines [77]. Here, CHEK1 is linked to small cell lung carcinoma.